PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7818372

Failure of test yolk buffer to decrease antisperm antibodies on sperm.

D Katsoff·J H Check·J Kozak
View original source ↗Export metadata ↓

Abstract

The objective of this study was to evaluate whether the suspension of sperm naturally bound or artificially coated with antisperm antibody (ASA) in test yolk buffer (TYB) will reduce the percentage of sperm positive for ASA. Attempts were made to repeat a study performed by Lam et al., in which they claimed a significant decrease in percentage of sperm positive for both IgA and IgG. Furthermore, the study attempted to determine if this methodology would similarly reduce the percentage of sperm naturally bound with ASA. There was no reduction in postincubation levels in percentage of sperm having attachment of IgA or IgG in either the sperm specimens naturally bound with ASA or donor sperm artificially coated with antibodies. Incubation in TYB does not appear to be an effective method to reduce the percentage of sperm bound with ASA. Possibly, it could reduce the amount of ASA bound to each sperm, but this would have to be proven by other studies.

Explore related subjects

AntibodiesCells, CulturedGlucoseHumansImmunoglobulin AImmunoglobulin GInfertility, MaleMaleSpermatozoaTromethamineJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Katsoff, J H Check, J Kozak. Failure of test yolk buffer to decrease antisperm antibodies on sperm.. https://doi.org/10.3109/01485019408987815

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗
PubMed1996

Beta-galactosidase enzymatic activity as a molecular probe to detect specific antibodies.

The main antigenic region of foot-and-mouth disease virus serotype C1, also called site A, has been inserted in zones of the beta-galactosidase important for the stabilization of the active site, causing important changes in the Km and the specific activity of the resulting enzymes. The peptide is displayed at the surface of the recombinant proteins and, in all the cases, presents a good antigenicity. Among the recombinant proteins constructed, in proteins M278VP1 and M275SVP1 the peptide is inserted in a large loop of the beta-galactosidase (amino acids 272-288) involved in the formation of the activating interface. In these constructs, the binding of the specific antibodies directed to the foreign peptide causes an increase of the beta-galactosidase activity up to about 200%. This phenomenon has been proved using monoclonal antibodies and also using polyclonal sera generated against the peptide. Different hypothesis of the mechanism of modulation upon antibody binding are discussed. This insertion site seems to be sensitive enough to enzymatic modulation mediated by antibody binding. We propose further exploring this insertion site as a tool for a rapid detection of specific antibodies in a quick and simple homogeneous assay based on the colorimetric determination of beta-galactosidase activity.

Antibodies↗